News & Media:Press Releases
- Solid Biosciences to Present at Barclays Global Healthcare Conference, March 7, 2023
- Solid Biosciences to Present at SVB Securities Global Biopharma Conference, February 8, 2023
- Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy, January 26, 2023
- Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases, January 11, 2023
- Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases, January 10, 2023
- Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer, January 9, 2023
- Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer, January 9, 2023
- Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference, January 9, 2023
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), December 5, 2022
- Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement, December 5, 2022
- Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio, December 1, 2022
- Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference, November 22, 2022
- Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results, November 10, 2022
- Solid Biosciences Announces a 1-for-15 Reverse Stock Split, October 27, 2022
- Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle, October 17, 2022
- Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function, October 13, 2022
- Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement, September 30, 2022
- Solid Biosciences to Participate at Upcoming Investor Conferences, September 29, 2022
- Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results, August 11, 2022
- Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences, June 23, 2022
- Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality, June 2, 2022
- Solid Biosciences to Participate at the Jefferies Healthcare Conference, June 2, 2022
- Solid Biosciences to Present at ASGCT 25th Annual Meeting and CureDuchenne 2022 FUTURES National Conference, May 17, 2022
- Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy, April 27, 2022
- Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results, April 25, 2022
- Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001, March 14, 2022
- Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference, February 10, 2022
- Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates, January 10, 2022
- Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference, January 6, 2022
- Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources, January 4, 2022
- Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results, November 3, 2021
- Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development, November 2, 2021
- Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit, October 21, 2021
- Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership, October 4, 2021
- Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001, September 29, 2021
- Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001, September 23, 2021
- Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001, September 20, 2021
- Solid Biosciences to Participate at Upcoming Investor Conferences, September 20, 2021
- Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021, August 24, 2021
- Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance, August 19, 2021
- Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance, August 19, 2021
- Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results, August 16, 2021
- Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development, July 2, 2021
- Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy, July 1, 2021
- Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer, June 7, 2021
- Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer, June 7, 2021
- Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference, May 26, 2021
- Solid Biosciences to Present at Upcoming Scientific Conferences, May 25, 2021
- Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results, May 14, 2021
- Solid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021, May 11, 2021
- Solid Biosciences Highlights Expertise in AAV Gene Therapy with Multiple Abstracts to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting, May 4, 2021
- Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit, April 20, 2021
- Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day, March 25, 2021
- Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option, March 23, 2021
- Solid Biosciences Announces Pricing of Public Offering of Common Stock, March 18, 2021
- Solid Biosciences Announces Proposed Public Offering of Common Stock, March 17, 2021
- Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort, March 15, 2021
- Solid Biosciences Reports Inducement Grant to New Chief Legal Officer, March 4, 2021
- Solid Biosciences Announces Appointments to Management Team and Board of Directors, March 4, 2021
- Efficacy and Safety Data from Solid Biosciences’ Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference, February 24, 2021
- Solid Biosciences to Present at Upcoming Investor Conferences, February 17, 2021
- Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference, January 6, 2021
- Solid Biosciences Announces $90 Million Private Placement, December 11, 2020
- Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update, November 5, 2020
- Solid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020, November 3, 2020
- Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy, October 23, 2020
- Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference, October 2, 2020
- Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial, October 1, 2020
- Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold, July 24, 2020
- Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors, June 18, 2020
- Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020, May 22, 2020
- Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting, May 14, 2020
- Solid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMD, May 7, 2020
- Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors, April 16, 2020
- Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update, March 12, 2020
- Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001, January 9, 2020
- Solid Biosciences Provides Data Update from SGT-001 Development Program, December 18, 2019
- Solid Biosciences Provides SGT-001 Program Update, November 12, 2019
- Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference, October 2, 2019
- Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders, September 5, 2019
- Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update, August 14, 2019
- Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors, July 26, 2019
- Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update, May 13, 2019
- Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting, April 15, 2019
- Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update, March 13, 2019
- Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy, February 7, 2019
- Solid Biosciences to Present at the J.P. Morgan Healthcare Conference, January 2, 2019
- Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update, November 13, 2018
- Solid Biosciences to Present at the Credit Suisse Healthcare Conference, November 9, 2018
- Solid Biosciences to Present at the Chardan Genetic Medicines Conference, October 5, 2018
- Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa, October 1, 2018
- Solid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors, September 13, 2018
- Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update, August 10, 2018
- Solid Biosciences Welcomes Industry Expert Dr. Martin Freed To Its Board Of Directors, June 26, 2018
- Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001, June 18, 2018
- Solid Biosciences Announces New Preclinical Data at the American Society of Gene and Cell Therapy Annual Meeting, May 18, 2018
- Solid Biosciences Announces Upcoming Preclinical Data Presentations, May 15, 2018
- Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update, May 10, 2018
- Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy, April 18, 2018
- Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update, March 29, 2018
- Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy, March 14, 2018
- Solid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option, January 30, 2018
- Solid Biosciences Announces Pricing of Initial Public Offering, January 25, 2018
- Solid Biosciences Initiates Clinical Trial for Gene Transfer Candidate SGT-001 in Patients with Duchenne Muscular Dystrophy, November 30, 2017
- Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences, September 20, 2017
- Solid Biosciences Strengthens Leadership Team to Advance Programs For Duchenne Muscular Dystrophy, June 7, 2017
- New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy, May 11, 2017
- Solid Biosciences Raises Up To $50 Million In Series C Financing, March 30, 2017
- Solid Biosciences Granted U.S. and E.U. Orphan Drug Designations for Lead Gene Therapy Candidate for Duchenne Muscular Dystrophy, October 24, 2016
- Solid GT Raises $42.5 million in Series B financing, November 25, 2015